Mr. Todd Shapiro reports

RED LIGHT HOLLAND ANNOUNCES FILAMENT HEALTH SHAREHOLDER APPROVAL OF ACQUISITION

Further to Red Light Holland Corp. and Filament Health Corp.'s joint press release dated March 10, 2026, and March 23, 2026, Filament's shareholders have approved each of the matters voted on at the Filament annual general and special meeting held on April 24, 2026, including approving the proposed plan of arrangement under the Business Corporations Act (British Columbia) with Red Light, which will result in the acquisition of all the issued and outstanding common shares of Filament by Red Light.

As disclosed in Filament's management information circular dated April 2, 2026, the special resolution approving the arrangement required the approval of: (i) 66.66 per cent of the votes cast by Filament shareholders present in person or represented by proxy at the Filament meeting; and (iii) a simple majority of votes cast by Filament shareholders present in person or represented by proxy at the Filament meeting after excluding votes cast by Filament shareholders who are required to be excluded to obtain minority approval in accordance with Section 8.1 of Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions.

A total of 196,282,175 votes, or approximately 99.99 per cent of the votes cast at the Filament meeting by Filament shareholders voting in person or represented by proxy were cast in favour of arrangement resolution. A total of 49,263,163 votes, or approximately 99.98 per cent of the votes were cast in favour of the arrangement resolution, excluding Filament shares required to be excluded to obtain minority approval in accordance with Section 8.1 of MI 61-101. In addition to the Filament interested parties (as defined in the Filament circular), 1.2 million Filament shares held by Ryan Moss were also excluded for the purposes of determining whether minority approval under MI 61-101 for the arrangement was obtained.

In aggregate, up to 182,447,452 common shares of Red Light are issuable under the arrangement (subject to adjustment), which includes shares issuable in settlement of certain of Filament's existing debt obligations and transaction bonuses. Following completion of the arrangement, Filament shareholders are expected to hold approximately 30 per cent of the outstanding Red Light shares. The consideration shares will be subject to resale restrictions, with 50 per cent released six months after closing, 25 per cent at nine months and the remaining 25 per cent at 12 months.

Filament will now apply for a final order of the Supreme Court of British Columbia approving the arrangement on April 28, 2026. Closing of the arrangement remains subject to certain customary closing conditions including court approval. Assuming the satisfaction of these closing conditions, the arrangement is expected to close on or about April 29, 2026.

Further information about the arrangement is available in the Filament circular and related proxy materials, which are available on SEDAR+ under Filament's issuer profile and on Filament's website.

About Red Light Holland Corp.

Red Light is an Ontario-based company advancing a focused strategy within the legal psychedelic sector, centred on voluntary data collection and R&D (research and development) initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, Red Light operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B (business-to-business) and DTC (direct-to-consumer) channels, in compliance with applicable laws.

About Filament Health Corp.

Filament is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates.

We seek Safe Harbor.